STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

The story
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
How this story developed
Full timelineAlto has tracked this across 2 days of coverage from 1 outlet.
- STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trialYou are here
Powered by Gab AI
The Story At A Glance
Reading this article now — analysis appears below
💡 AI analysis provides alternative perspectives on current events